Form 4: Emergent BioSolutions Executive Sells Shares

Emergent BioSolutions SVP, Products Business Paul Anthony Williams reported a sale of 3,000 common shares on July 1, 2026, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Paul Anthony Williams, SVP, Products Business at Emergent BioSolutions Inc. (EBS), sold 3,000 shares of common stock on July 1, 2026.
• The sale was conducted under a trading plan adopted on November 14, 2025, designed to comply with Rule 10b5-1(c) of the Securities Exchange Act of 1934.
• The shares were sold at a weighted average price of $8.40, with individual transactions ranging from $8.31 to $8.46.
• Following these transactions, Mr. Williams beneficially owns 159,098 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. The transaction is a routine insider sale under a pre-established plan, with no immediate indication of significant positive or negative company performance.

Negatives

• An executive sold a portion of their holdings, reducing their direct beneficial ownership.

Risks

• The sale was executed under a pre-arranged trading plan, which is a standard practice for executives to diversify holdings or manage personal finances without implying negative non-public information about the company.

Future Outlook

The filing does not contain forward-looking statements or guidance. It is a report of a past transaction.

Industry Context

StockSavvy.ai notes that Form 4 filings report insider transactions. Sales by executives, especially when conducted under a Rule 10b5-1 plan, are common and do not necessarily indicate a negative outlook on the company's future performance. These plans allow executives to sell shares at predetermined times or prices, providing a defense against insider trading allegations.

Stakeholder Impact

• Shareholders: The sale represents a reduction in the executive's direct ownership, but the execution under a 10b5-1 plan mitigates concerns about insider knowledge impacting the market.

Key Dates

Keywords

Emergent BioSolutions, EBS, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, Paul Anthony Williams, Beneficial Ownership